Want to see SE:ATORX full AI Analyst Report?
ATORX Stock Chart & Stats
kr0.03
>-kr0.01(-8.19%)
At close: 4:00 PM EDT
kr0.03
>-kr0.01(-8.19%)
Day’s Range― - ―
52-Week Rangekr0.02 - kr1.07
Previous CloseN/A
Volume25.04M
Average Volume (3M)21.79M
Market Cap
kr172.73M
Enterprise Valuekr122.60
Total Cash (Recent Filing)kr16.61M
Total Debt (Recent Filing)kr29.93M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding6,909,175,300
10 Day Avg. Volume32,403,234
30 Day Avg. Volume21,789,510
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageThe sharp reduction in debt-to-equity indicates improved leverage and may reflect recapitalization or debt reduction. A less debt-heavy balance sheet can reduce financial strain and provide greater flexibility to support clinical development, although the company remains financially fragile.
Specialized Oncology PipelineA focused oncology platform built around antibody immunotherapies gives Alligator a defined scientific and commercial direction. Targeting immune checkpoints and costimulatory pathways aligns its pipeline with established areas of cancer drug development and potential partnering interest.
Improving Free Cash Flow TrendThe year-over-year improvement in free cash flow is a constructive operating trend, suggesting some reduction in cash deterioration relative to the prior period. If sustained, this could extend financial runway, though current cash generation remains insufficient to fund operations independently.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow shows that the business is consuming substantial cash rather than funding development internally. Continued burn increases dependence on external financing and can constrain the pace of clinical investment or force dilutive capital actions.
Limited Commercial ScaleMinimal and declining revenue, combined with a deeply negative net margin, indicates that the company has not yet achieved meaningful commercial scale. High fixed R&D costs therefore remain unsupported by recurring operating income, leaving profitability dependent on future pipeline or partnering success.
Thin Equity BaseA very thin equity base leaves limited balance-sheet capacity to absorb continuing losses or finance clinical programs. Heavy negative ROE confirms that capital is being consumed without producing returns, increasing the likelihood that future operations will require additional external funding.
Alligator Bioscience AB News
ATORX FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was kr0.02 and its highest was kr1.07 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr172.73M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Oct 22, 2026 which is in 45 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Aug 26, 2026. The company reported -kr0.041 earnings per share for the quarter.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 6,909,175,300 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.041 in its last earnings report. Following the earnings report the stock price went up 21.053%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in SE:ATORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―